ViaCell Announces Completion Of CB001 Phase I Clinical Trial

ViaCell, Inc. (Nasdaq: VIAC) today announced that it has enrolled and treated the last patient in the CB001 Phase I clinical trial and has begun the 100-day post-transplant follow-up. CB001 is an investigational therapy being studied as a potential therapeutic option for people who need stem cell transplants, such as bone marrow, for hematopoietic recovery after...

25/07/2006